In a small randomized trial of psilocybin-assisted therapy for adults with major depressive disorder, the therapeutic alliance between participants and facilitators strengthened from the final preparation session to one week after the intervention. A stronger alliance before the psilocybin sessions predicted lower depression scores at 4 weeks, 6 months, and 12 months afterward. Stronger alliance also correlated with more intense mystical experiences and psychological insight during the drug sessions, which in turn predicted better depression outcomes. The findings suggest the therapeutic relationship is important for treatment success.
Certain subtypes of psychedelic experiences consistently and predictably reduce symptoms of depression and anxiety. The findings indicate that distinct patterns within a psychedelic journey can be linked to specific therapeutic outcomes, suggesting that the structure of the experience itself plays a role in mental health benefits.
Among 346 LGBTQIA+ individuals, mostly White and in their early 30s, those who used psychedelics reported improvements in mental health and shifts in gender and sexual identity. Retrospective reports showed large reductions in traumatic stress, depression, and anxiety, along with increased psychological flexibility. A significant link emerged between the intensity of the psychedelic experience and greater self-acceptance and sexual identity exploration. Most participants (77%) saw therapeutic potential in psychedelics for gender dysphoria, and 65% reported changes in gender identity attitudes after use. The findings suggest psychedelics may support identity exploration and mental health in this population, warranting further research.